Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/25/2024 | Buy → Neutral | BTIG Research | |
| 7/28/2023 | $10.00 | Overweight | Piper Sandler |
| 6/15/2023 | $15.00 | Buy | BTIG Research |
| 11/12/2021 | $12.00 → $16.00 | Buy | Truist Securities |
For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us
8-K - Beyond Air, Inc. (0001641631) (Filer)
10-K - Beyond Air, Inc. (0001641631) (Filer)
8-K - Beyond Air, Inc. (0001641631) (Filer)
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer's disease, and a subsidiary of Beyond Air (NASDAQ:XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, "Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models," presents compelling evidence of a novel mechanism in the early sta
First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ:XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round.
The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECISTThe study will recruit patients from four sites across Israel HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an imm
4 - Beyond Air, Inc. (0001641631) (Issuer)
4 - Beyond Air, Inc. (0001641631) (Issuer)
4 - Beyond Air, Inc. (0001641631) (Issuer)
4 - Beyond Air, Inc. (0001641631) (Issuer)
4 - Beyond Air, Inc. (0001641631) (Issuer)
4 - Beyond Air, Inc. (0001641631) (Issuer)
BTIG Research downgraded Beyond Air from Buy to Neutral
Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00
BTIG Research initiated coverage of Beyond Air with a rating of Buy and set a new price target of $15.00